Gardiquimod trifluoroacetate is primarily used in immunological research as a potent agonist for Toll-like receptor 7 (TLR7). It is widely employed to stimulate immune responses in experimental studies, particularly in the investigation of innate immunity and antiviral mechanisms. Researchers utilize it to induce the production of cytokines, such as interferon-alpha, in immune cells, which helps in understanding immune signaling pathways and developing therapeutic strategies for viral infections and cancer. Additionally, it serves as a valuable tool in the development of vaccine adjuvants, enhancing the efficacy of vaccines by boosting the immune system's response. Its application extends to preclinical studies focused on autoimmune diseases, where modulating TLR7 activity can provide insights into disease mechanisms and potential treatments.